Rilmenidine in the hypertensive type-2 diabetic: A controlled pilot study versus captopril

Abstract

Rilmenidine is an innovative antihypertensive agent that binds specifically to I>1 imidazoline receptors. The antihypertensive efficacy of rilmenidine in treating type-2 diabetics has been demonstrated, and is associated with very good clinical and laboratory tolerance. This was a 6-month, double-blind, randomized, controlled study comparing the effects of rilmenidine and captopril on the progression of microalbuminuria in a population of patients with mild-to-moderate hypertension [90 mmHg < diastolic blood pressure (DBP) < 110 mmHg], type-2 diabetes, and microalbuminuria (30 mg/24 h